Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARα/γ and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes

Pharmacology

Volumn 83, Issue 1, 2008, Pages 18-25

  Hua, Yinan ^a   Xue, Jie ^a   Sun, Fan ^a   Zhu, Lujia ^a   Xie, Meilin ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Aspirin; Macrophages; Matrix metalloproteinase; Nuclear factor B; Peroxisome proliferator activated receptors ; Tissue inhibitors of metalloproteinases

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACETYLSALICYLIC ACID; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME RELEASE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIMP GENE; UPREGULATION;

ASPIRIN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MONOCYTES; PLATELET AGGREGATION INHIBITORS; PPAR ALPHA; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UP-REGULATION;

EID: 54849423350     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000166183     Document Type: Article

References (34)

1. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-262.
2. Jones CB, Sane DC, Herrington DM: Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812-823.
3. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
4. Loftus IM, Naylor AR, Bell PR, Thompson MM: Plasma MMP-9-a marker of carotid plaque instability. Eur J Vasc Endovasc Surg 2001;21:17-21.
5. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al: Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372.
6. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-198.
7. Vincenti MP: The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes: transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 2001;151:121-148.
8. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514.
9. Duez H, Fruchart JC, Staels B: PPAR in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001;8:187-194.
10. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-25580.
11. Shu H, Wong B, Zhou GC, Li Y, Berger J, Woods JW, et al: Activation of PPARα or PPARγ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000;267:345-349.
12. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, et al: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-288.
13. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
14. Vinals M, Bermudez I, Llaverias G, Alegret M, Sanchez RM, Vazquez-Carrera M, et al: Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res 2005;66:141-149.
15. Tancevski A, Wehinger W, Schgoer P, Eller B, Foeger JR, Patsch A: Influence of aspirin on expression and function of scavenger receptor-BI within primary human macrophages: a new atheroprotective mechanism of aspirin? Atherosclerosis 2005;6(suppl):98.
16. Karna E, Palka JA: Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation. Eur J Pharmacol 2002;443:1-6.
17. Mehta JL, Chen J, Yu F, Li DY: Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 2004;64:243-249.
18. Sampson M, Wall S, Baugh M, Worley J, Davies I, Hughes D, et al: Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy. Diabetes Res Clin Pract 2006;71:45-51.
19. Steer KA, Wallace TM, Bolton CH, Hartog M: Aspirin protects low density lipoprotein from oxidative modification. Heart 1997;77:333-337.
20. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA: Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-720.
21. Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, Emeis JJ: Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic apoE *3Leiden mice. Arterioscler Thromb Vasc Biol 2006;26:2560-2566.
22. Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ: Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005;25:1903-1909.
23. Calkin AC, Cooper ME, Jandeleit-Dahm KA: Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 2006;49:766-774.
24. Chase AJ, Bond M, Crook MF, Newby AC: Role of nuclear factor-κB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002;22:765-771.
25. Bond M, Baker AH, Newby AC: Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999;264:561-567.
26. Bond M, Chase AJ, Baker AH, Newby AC: Inhibition of transcription factor NF-kappa B reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001;50:556-565.
27. Chase AJ, Newby AC: Inhibition of transcription factor NF-kappa B in human vascular smooth muscle cells reduces expression of matrix degrading enzymes implicated in atherosclerotic plaque instability. Heart 2000;5:15-18.
28. Li H, Ruan XZ, Moorhead JF, Powis SH, Varghese Z: Omega 3 polyunsaturated fatty acids (PUFA) inhibits NF kappa B activity in LPS-stimulated HK-2 cells through a PPAR gamma mediated pathway. Nephrol Dial Transpl 2003;18:22.
29. Muller DN, Theuer J, Shagdarsuren E, Kargel E, Honeck H, Park JK, et al: A PPAR-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Nephrol Dial Transplant 2003;18:318-319.
30. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferators activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
31. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-959.
32. Rouis M, Adamy C, Duverger N, Lesnik P, Horellou P, Moreau M, et al: Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999;100:533-540.
33. Dellery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR: Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999;99:3199-3205.
34. Jo Y, Yeon J, Kim HJ, Lee ST: Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinases-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Biochem J 2000;345:511-519.